Terms: = Kidney tumors AND CYLD, CYLD1, 1540, ENSG00000083799, USPL2, KIAA0849, CYLDI, CDMT, HSPC057, FLJ31664, FLJ20180, EAC AND Treatment
10 results:
1. Efficacy and safety of neoadjuvant immunotherapy in resectable esophageal or gastroesophageal junction carcinoma: A pooled analysis of prospective clinical trials.
Zhu J; Leng X; Gao B; Wang B; Zhang H; Wu L; Ma J; Tan Y; Peng L; Han Y; Wang Q
Front Immunol; 2022; 13():1041233. PubMed ID: 36591306
[TBL] [Abstract] [Full Text] [Related]
2. [Safety and effectiveness of oxaliplatin combined with capecitabine or oxaliplatin combined with S-1 neoadjuvant chemotherapy in the treatment of advanced gastric cancer].
Xie BW; Zang L; Ma JJ; Sun J; Yang X; Wang ML; Lu AG; Hu WG; Zheng MH
Zhonghua Wei Chang Wai Ke Za Zhi; 2021 Feb; 24(2):138-144. PubMed ID: 33508919
[No Abstract] [Full Text] [Related]
3. Targeted delivery of quercetin via pH-responsive zinc oxide nanoparticles for breast cancer therapy.
Sadhukhan P; Kundu M; Chatterjee S; Ghosh N; Manna P; Das J; Sil PC
Mater Sci Eng C Mater Biol Appl; 2019 Jul; 100():129-140. PubMed ID: 30948047
[TBL] [Abstract] [Full Text] [Related]
4. What Constitutes Optimal Management of T1N0 Esophageal Adenocarcinoma?
Ramay FH; Vareedayah AA; Visrodia K; Iyer PG; Wang KK; Eluri S; Shaheen NJ; Reddy R; Martin LW; Greenwald BD; Edwards MA
Ann Surg Oncol; 2019 Mar; 26(3):714-731. PubMed ID: 30607765
[TBL] [Abstract] [Full Text] [Related]
5. Abemaciclib Inhibits Renal Tubular Secretion Without Changing Glomerular Filtration Rate.
Chappell JC; Turner PK; Pak YA; Bacon J; Chiang AY; Royalty J; Hall SD; Kulanthaivel P; Bonventre JV
Clin Pharmacol Ther; 2019 May; 105(5):1187-1195. PubMed ID: 30449032
[TBL] [Abstract] [Full Text] [Related]
6. Analysis of radiofrequency ablation of small renal tumors in patients at high anesthetic and surgical risk: urologist experience with follow-up results in the initial six months.
Yuksel MB; Karakose A; Gumus B; Tarhan S; Atesci YZ; Akan Z
Asian Pac J Cancer Prev; 2014 Jan; 14(11):6637-41. PubMed ID: 24377580
[TBL] [Abstract] [Full Text] [Related]
7. Evaluation of antitumor efficacy and toxicity of novel 6-nitro-2-(3-chloropropyl)-1H-benz[de]isoquinoline-1,3-dione in vivo in mouse.
Mukherjee A; Dutta S; Sanyal U
J Cancer Res Ther; 2013; 9(3):442-6. PubMed ID: 24125980
[TBL] [Abstract] [Full Text] [Related]
8. Progression free survival of first line vascular endothelial growth factor-targeted therapy is an important prognostic parameter in patients with metastatic renal cell carcinoma.
Seidel C; Busch J; Weikert S; Steffens S; Fenner M; Ganser A; Grünwald V
Eur J Cancer; 2012 May; 48(7):1023-30. PubMed ID: 22436979
[TBL] [Abstract] [Full Text] [Related]
9. Evaluation of dimethoxydop-NU as a novel anti-tumor agent.
Mukherjee A; Dutta S; Sanyal U
J Exp Clin Cancer Res; 2007 Dec; 26(4):489-97. PubMed ID: 18365543
[TBL] [Abstract] [Full Text] [Related]
10. Palliative nutritional intervention in addition to cyclooxygenase and erythropoietin treatment for patients with malignant disease: Effects on survival, metabolism, and function.
Lundholm K; Daneryd P; Bosaeus I; Körner U; Lindholm E
Cancer; 2004 May; 100(9):1967-77. PubMed ID: 15112279
[TBL] [Abstract] [Full Text] [Related]
